Trials (North Estonia Medical Centre) - Revision history

Lucas: Update categories.

2025-12-06T12:42:09Z

Update categories.

← Older revision		Revision as of 12:42, 6 December 2025
Line 632:		Line 632:
	<span style="display:none">hasTrialTitle::Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma</span>		<span style="display:none">hasTrialTitle::Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma</span>
	<span style="display:none">hasTrialTitle::A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU)</span>		<span style="display:none">hasTrialTitle::A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU)</span>
			<span style="display:none">hasCancerType::C00-D48: All neoplasms</span>
			<span style="display:none">hasCancerType::C00-C97: All cancer types</span>
			<span style="display:none">hasCancerType::C00-C14: Mouth/throat cancers</span>
			<span style="display:none">hasCancerType::C15-C26: Digestive system cancers</span>
			<span style="display:none">hasCancerType::C30-C39: Lung/chest cancers</span>
			<span style="display:none">hasCancerType::C40-C41: Bone cancers</span>
			<span style="display:none">hasCancerType::C43-C44: Skin cancers/melanoma</span>
			<span style="display:none">hasCancerType::C45-C49: Soft tissue cancer</span>
			<span style="display:none">hasCancerType::C50: Breast cancer</span>
			<span style="display:none">hasCancerType::C51-C58: Female genitalia cancers</span>
			<span style="display:none">hasCancerType::C60-C63: Male genitalia cancer</span>
			<span style="display:none">hasCancerType::C64-C68: Urinary system cancers</span>
			<span style="display:none">hasCancerType::C69-C72: Eye and brain cancer</span>
			<span style="display:none">hasCancerType::C73-C75: Thyroid and other gland cancers</span>
			<span style="display:none">hasCancerType::C76-C80: Cancers of unknown or unspecified areas</span>
			<span style="display:none">hasCancerType::C81-C96: Cancers of the blood and immune system</span>
			<span style="display:none">hasCancerType::C97-C97: Cancers in multiple locations from the start</span>
			<span style="display:none">hasCancerType::D00-D09: Early-stage cancers not yet spread</span>
			<span style="display:none">hasCancerType::D10-D36: Benign tumour</span>
			<span style="display:none">hasCancerType::D37-D48: Growths of uncertain nature</span>
			<span style="display:none">hasCancerType::unknown</span>

Francine at 16:32, 2 December 2025

2025-12-02T16:32:55Z

← Older revision		Revision as of 16:32, 2 December 2025
Line 2:		Line 2:
	<span style="display:none">forproviders</span>		<span style="display:none">forproviders</span>
	<span style="display:none">forresearchers</span>		<span style="display:none">forresearchers</span>
	<span style="display:none">~~estonia~~</span>		<span style="display:none">estoniacountry</span>
	Go back to [[North Estonia Medical Centre]]		Go back to [[North Estonia Medical Centre]]

Lucas: Update categories.

2025-12-02T14:00:30Z

Update categories.

@@ Line 1: / Line 1: @@
-{{forpatients}}
+<span style="display:none">forpatients</span>
-{{forproviders}}
+<span style="display:none">forproviders</span>
-{{forresearchers}}
+<span style="display:none">forresearchers</span>
-{{estonia}}
+<span style="display:none">estonia</span>
 Go back to [[North Estonia Medical Centre]]
@@ Line 575: / Line 575: @@
   '''Recruitment Status''': TERMINATED
   '''Condition''': Small Cell Lung Cancer

Victor at 23:38, 5 November 2024

2024-11-05T23:38:51Z

← Older revision		Revision as of 23:38, 5 November 2024
Line 2:		Line 2:
	{{forproviders}}		{{forproviders}}
	{{forresearchers}}		{{forresearchers}}
			{{estonia}}
	Go back to [[North Estonia Medical Centre]]		Go back to [[North Estonia Medical Centre]]

Francine at 14:35, 4 January 2024

2024-01-04T14:35:46Z

← Older revision		Revision as of 14:35, 4 January 2024
Line 135:		Line 135:
	'''Condition''': Chronic Lymphocytic Leukemia		'''Condition''': Chronic Lymphocytic Leukemia
	'''NCTID''': NCT02562443		'''NCTID''': NCT02562443
	'''Title''': [[hasTrialTitle::Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA		'''Title''': [[hasTrialTitle::Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA]]
	'''Study Summary''': The study's primary objective \[in a population of patients with MDS after failure of treatment with azacitidine (AZA) or decitabine (DAC)\], is to compare the overall survival (OS) of patients in the rigosertib group vs the Physician's Choice group, in all patients and in a subgroup of patients with IPSS-R very high risk]].		'''Study Summary''': The study's primary objective \[in a population of patients with MDS after failure of treatment with azacitidine (AZA) or decitabine (DAC)\], is to compare the overall survival (OS) of patients in the rigosertib group vs the Physician's Choice group, in all patients and in a subgroup of patients with IPSS-R very high risk.
	'''Sponsor''': Onconova Therapeutics, Inc.		'''Sponsor''': Onconova Therapeutics, Inc.
	'''Intervention''': rigosertib		'''Intervention''': rigosertib

Francine at 14:33, 4 January 2024

2024-01-04T14:33:33Z

← Older revision		Revision as of 14:33, 4 January 2024
Line 75:		Line 75:
	'''Condition''': HPV Infection		'''Condition''': HPV Infection
	'''NCTID''': NCT05609968		'''NCTID''': NCT05609968
	'''Title''': [[hasTrialTitle::Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50 (MK-3475-D46)]]		'''Title''': [[hasTrialTitle::Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)]]
	'''Study Summary''': The purpose of this study is to compare pembrolizumab (MK-3475) in combination with sacituzumab govitecan with pembrolizumab alone with respect to progression-free survival (PFS) and overall survival (OS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by blinded independent central review (BICR) among adults with metastatic non-small cell lung cancer (NSCLC) with programmed cell death ligand 1 (PD-L1) tumor proportion score (TPS) ≥50%).		'''Study Summary''': The purpose of this study is to compare pembrolizumab (MK-3475) in combination with sacituzumab govitecan with pembrolizumab alone with respect to progression-free survival (PFS) and overall survival (OS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by blinded independent central review (BICR) among adults with metastatic non-small cell lung cancer (NSCLC) with programmed cell death ligand 1 (PD-L1) tumor proportion score (TPS) ≥50%).
	'''Sponsor''': Merck Sharp & Dohme LLC		'''Sponsor''': Merck Sharp & Dohme LLC

Francine at 14:33, 4 January 2024

2024-01-04T14:33:09Z

← Older revision		Revision as of 14:33, 4 January 2024
Line 75:		Line 75:
	'''Condition''': HPV Infection		'''Condition''': HPV Infection
	'''NCTID''': NCT05609968		'''NCTID''': NCT05609968
	'''Title''': [[hasTrialTitle::Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)]]		'''Title''': [[hasTrialTitle::Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50 (MK-3475-D46)]]
	'''Study Summary''': The purpose of this study is to compare pembrolizumab (MK-3475) in combination with sacituzumab govitecan with pembrolizumab alone with respect to progression-free survival (PFS) and overall survival (OS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by blinded independent central review (BICR) among adults with metastatic non-small cell lung cancer (NSCLC) with programmed cell death ligand 1 (PD-L1) tumor proportion score (TPS) ≥50%).		'''Study Summary''': The purpose of this study is to compare pembrolizumab (MK-3475) in combination with sacituzumab govitecan with pembrolizumab alone with respect to progression-free survival (PFS) and overall survival (OS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by blinded independent central review (BICR) among adults with metastatic non-small cell lung cancer (NSCLC) with programmed cell death ligand 1 (PD-L1) tumor proportion score (TPS) ≥50%).
	'''Sponsor''': Merck Sharp & Dohme LLC		'''Sponsor''': Merck Sharp & Dohme LLC

Francine at 14:32, 4 January 2024

2024-01-04T14:32:29Z

Show changes

Francine: Created page with "{{forpatients}} {{forproviders}} {{forresearchers}} Go back to North Estonia Medical Centre '''NCTID''': NCT02205047 '''Title''': Neoadjuvant Study Using Trastuzumab or Trastuzumab With Pertuzumab in Gastric or Gastroesophageal Junction Adenocarcinoma '''Study Summary''': The purpose of this study is to find out whether either trastuzumab or the combination of trastuzumab and pertuzumab with standard chemotherapy shows more activity against gastro-oesophageal aden..."

2023-12-01T20:45:06Z

Created page with "{{forpatients}} {{forproviders}} {{forresearchers}} Go back to North Estonia Medical Centre '''NCTID''': NCT02205047 '''Title''': Neoadjuvant Study Using Trastuzumab or Trastuzumab With Pertuzumab in Gastric or Gastroesophageal Junction Adenocarcinoma '''Study Summary''': The purpose of this study is to find out whether either trastuzumab or the combination of trastuzumab and pertuzumab with standard chemotherapy shows more activity against gastro-oesophageal aden..."

Show changes